Concert Pharma Aces Second Trial For Patchy Hair Loss Hopeful

• Concert Pharmaceuticals Inc (NASDAQ: CNCE) announced topline results from its second Phase 3 trial, THRIVE-AA2, evaluating CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.

• The primary efficacy endpoint was met with statistical significance in the 8 mg twice-daily and 12 mg twice-daily dose groups relative to placebo.

• A statistically significant proportion of patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 experienced greater scalp regrowth compared to placebo.

• Related: Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss.

• The proportion of patients achieving a SALT score of 20 or less (meaning 20% or less scalp hair loss) was 38.3% in the 12 mg twice-daily dose group and 33% in the 8 mg twice-daily dose, compared to 0.8% in the placebo group.

• 47% of patients in the 8 mg twice-daily group and 52% in the 12 mg twice-daily group reported being "satisfied" or "very satisfied," compared to 2% of patients in the placebo group.

• The safety profile seen with CTP-543 in THRIVE-AA2 was consistent with previous studies.

• Concert plans to submit to FDA marketing application in 1H of 2023.

• Price Action: CNCE shares are up 8.57% at $6.08 on the last check Monday.

See more from Benzinga

• After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program

• Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.